Rensun Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 70.05%
- Profit Growth -134.11%
- Ebitda -28.83%
- Net Worth -15.25%
- Total Assets 54.26%
About Rensun Pharmaceuticals
Rensun Pharmaceuticals Private Limited (RPPL) is a Private Limited Indian Non-Government Company incorporated in India on 16 January 2006 and has a history of 19 years and one month. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Renu Tiwari and Sanjay Tiwari serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24230MH2006PTC158896
- Company No.
158896
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Jan 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Rensun Pharmaceuticals Private Limited offer?
Rensun Pharmaceuticals Private Limited offers a wide range of products and services, including Ayurvedic & Herbal Extracts, Herbal Extracts.
Who are the key members and board of directors at Rensun Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Renu Tiwari  | Director | 16-Jan-2006 | Current |
| Sanjay Tiwari | Director | 16-Jan-2006 | Current |
Financial Performance of Rensun Pharmaceuticals.
Rensun Pharmaceuticals Private Limited, for the financial year ended 2017, experienced significant growth in revenue, with a 70.05% increase. The company also saw a substantial fall in profitability, with a 134.11% decrease in profit. The company's net worth observed a substantial decline by a decrease of 15.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rensun Pharmaceuticals?
In 2017, Rensun Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Mol Chem LimitedSanjay Tiwari is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rensun Pharmaceuticals?
Unlock and access historical data on people associated with Rensun Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rensun Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rensun Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.